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Delayed Chemotherapy-Induced
Nausea and Vomiting: Pathogenesis,
Incidence, and Current Management
Bernardo L. Rapoport*
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
Even when chemotherapy-induced nausea and vomiting (CINV) can be effectively
controlled in the acute phase, it may still occur in the delayed phase. Identifying at-
risk patients is complex and requires consideration of clinical, personal, demographic,
and behavioral factors. Delayed CINV has a significant detrimental effect on patients’
daily life and is responsible for significant healthcare resource utilization. Patients who
do not experience acute CINV are not necessarily exempt from delayed CINV, and
healthcare professionals have been shown to underestimate the incidence of delayed
CINV. Failure to protect against CINV during the first cycle of chemotherapy is the
most significant independent risk factor for delayed CINV during subsequent cycles.
Addition of a neurokinin-1 receptor antagonist to antiemetic prophylactic regimens
involving a 5-hydroxytryptamine type 3 receptor antagonist and a corticosteroid helps
to ameliorate delayed CINV, particularly vomiting. Netupitant and rolapitant are second-
generation neurokinin-1 receptor antagonists that provide effective prophylaxis against
delayed chemotherapy-induced vomiting and also have an antinausea benefit. All of
the neurokinin-1 receptor antagonists with the exception of rolapitant inhibit or induce
cytochrome P450 3A4 (CYP3A4), and a reduced dose of dexamethasone (a CYP3A4
substrate) should be administered with aprepitant or netupitant; by contrast, this is not
necessary with rolapitant. Here we review specific challenges associated with delayed
CINV, its pathophysiology, epidemiology, treatment, and outcomes relative to acute
CINV, and its management within the larger context of overall CINV.
Keywords: antiemetics, delayed chemotherapy-induced nausea and vomiting, emesis, highly emetogenic
chemotherapy, moderately emetogenic chemotherapy, nausea, neurokinin-1 receptor antagonists, vomiting
INTRODUCTION
Nausea and vomiting are the most feared side effects of cytotoxic chemotherapy (de Boer-Dennert
et al., 1997; Sun et al., 2005) and can have a deleterious effect on health-related quality of
life (Bloechl-Daum et al., 2006; Hilarius et al., 2012), compromise treatment outcomes (Vidall
et al., 2011; Jordan et al., 2015; Van Laar et al., 2015; National Comprehensive Cancer Network,
2016; Navari, 2016), and increase healthcare resource utilization (Schwartzberg L. et al., 2015).
Chemotherapy-induced nausea and vomiting (CINV) typically presents in two phases, the acute
phase and the delayed phase, over a 5-day period (Navari and Aapro, 2016). Acute CINV occurs
within 1–2 h of chemotherapy administration and can last for up to 24 h; delayed CINV presents
more than 24 h after chemotherapy administration, and it is most frequently reported with
the agents cisplatin, carboplatin, cyclophosphamide, and doxorubicin (National Comprehensive
Cancer Network, 2016).
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While acute CINV is reasonably well managed with serotonin
(5-hydroxytryptamine) type 3 (5-HT3) receptor antagonists in
the majority of patients (Jordan et al., 2007), delayed CINV
continues to present a treatment challenge (Grunberg et al.,
2004; Hsieh et al., 2015; Baba et al., 2016). This review discusses
the pathophysiology, burden of illness, and treatment outcomes
associated with delayed CINV, together with advances and future
directions for management.
The Pathophysiology of Delayed CINV
Chemotherapy-induced nausea and vomiting is a highly complex
reflex that involves contributory pathways from both the central
and peripheral nervous systems. While the pathophysiology of
emesis is not completely understood, it is currently thought that
chemotherapy-induced release of neurotransmitters stimulates
receptors on the terminals of afferent nerves in various locations,
including the gastrointestinal tract, cerebral cortex and thalamus,
vestibular region, and area postrema, which project to the nucleus
tractus solitarius (NTS) located in the brain stem (Aapro et al.,
2014a; Babic and Browning, 2014; National Comprehensive
Cancer Network, 2016; Navari and Aapro, 2016). The NTS
plays a dominant role in coordinating the autonomic processes
involved in vomiting, such as swallowing, salivation, respiration,
abdominal muscle contraction and relaxation, and intestinal
contraction and relaxation (Babic and Browning, 2014). In
addition, neurotransmitters may directly stimulate receptors
located in the area postrema of the brain (known as the
chemoreceptor trigger zone), which also activates the NTS
(Aapro et al., 2014a). Neurotransmitters that have been identified
as important mediators of CINV include serotonin and substance
P (Navari and Aapro, 2016).
The typical pattern of CINV is shown in Figure 1. The
acute phase occurs within the first 24 h after chemotherapy
and is largely mediated by 5-HT3 receptors in the intestine
(Navari, 2016). In this phase, free radicals generated after
FIGURE 1 | Pattern of cisplatin-induced delayed emesis. This illustrates
the biphasic pattern of emesis after the administration of high-dose cisplatin,
with the maximum intensity seen with the initial 24 h, followed by a second
peak of less intense nausea and emesis on days 2 and 3. Reprinted from
Springer Drugs 1996 Nov; 52 (5): 639–648, Tavorath R and Hesketh PJ
(© Adis International Limited. All rights reserved). With permission of Springer.
administration of chemotherapy induce the release of serotonin
from enterochromaffin cells located in the intestinal mucosa
(Aapro et al., 2014a; Navari, 2016). Serotonin then interacts with
5-HT3 receptors located on vagal afferent nerves in the intestinal
wall, which project to the area postrema and NTS, stimulating the
vomiting reflex (Aapro et al., 2014a). Serotonin may also directly
interact with 5-HT3 receptors on the area postrema (Aapro
et al., 2014a). Acute CINV is therefore particularly sensitive to
5-HT3 receptor antagonists (Aapro, 2005) (Figure 1); however,
these agents have little impact on delayed CINV (Aapro, 2005),
suggesting that different pathophysiologic mechanisms may be at
play during the second emetic phase.
The delayed phase of CINV starts on day 2 after
chemotherapy and can last up to day 5. Delayed CINV is
predominantly driven by a central pathway involving the
neurotransmitter/neuromodulator substance P, which is a
member of the mammalian tachykinin family of peptides
(Garcia-Recio and Gascon, 2015). Substance P is released
from neurons in response to chemotherapy and binds
to neurokinin-1 (NK-1) receptors in the area postrema
and NTS, thereby mediating the induction of vomiting
(Armstrong et al., 1981; Aapro et al., 2014a). The dominant
role of substance P in delayed CINV is demonstrated by
the effectiveness of NK-1 receptor antagonists in preventing
CINV during this phase (Navari, 2016) (Figure 1). NK-1
receptors are also located on vagal afferent terminals in the
gastrointestinal tract, suggesting that substance P released from
enterochromaffin cells in response to chemotherapy may also
play an auxiliary role in the acute phase of CINV (Hesketh,
2008).
Classification of Emetic Agents
The emetogenicity of chemotherapy refers to its capacity
to induce nausea and vomiting when administered without
adequate antiemetic prophylaxis. One of the most commonly
used schemes divides chemotherapeutic agents into four
categories (high, moderate, low, and minimal), depending on
the percentage of patients who would experience emesis in
the acute phase while receiving the agent without adequate
antiemetic prophylaxis (Hesketh et al., 1997). In the absence
of such prophylaxis, it is estimated that over 90% of patients
exposed to highly emetogenic chemotherapy (HEC) and
between 30 and 90% of patients exposed to moderately
emetogenic chemotherapy (MEC) will experience acute-phase
CINV (Table 1). Emetogenic categories are regularly updated
by guidelines groups to incorporate new agents or new data
from existing agents (Basch et al., 2011; Hesketh et al.,
2016a; National Comprehensive Cancer Network, 2016). One
particularly significant change for CINV was the reclassification
of anthracycline-cyclophosphamide (AC)–based chemotherapy
from the moderately emetogenic category to the highly
emetogenic category in 2011. In addition, while carboplatin-
based chemotherapy is defined as MEC, the Multinational
Association of Supportive Care in Cancer (MASCC) and
European Society for Medical Oncology (ESMO) guidelines were
recently updated to recommend that CINV associated with
carboplatin therapy be treated in the same way as HEC, with an
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TABLE 1 | Emetogenic risk categories for antineoplastic agents (based on
acute emetogenicity) (Hesketh et al., 1997).
Emetogenic
risk
Frequency of emesis
in the absence of
effective antiemetic
prophylaxis
Intravenous
antineoplastic agents
High >90% • AC combination:
doxorubicin or epirubicin +
cyclophosphamide
• Carmustine >250 mg/m2
• Cisplatin
• Cyclophosphamide
>1,500 mg/m2
• Dacarbazine
• Doxorubicin ≥60 mg/m2
• Epirubicin ≥90 mg/m2
• Ifosfamide ≥2 g/m2 per
dose
• Mechlorethamine
• Streptozocin
Moderate 30–90% • Aldesleukin >12–15
million IU/m2
• Amifostine >300 mg/m2
• Arsenic trioxide
• Bendamustine
• Busulfan
• Carboplatina
• Carmustinea
≤250 mg/m2
• Cloforabine
• Cyclophosphamide
<1,500 mg/m2
• Cytarabine >200 mg/m2
• Dactinomycina
• Daunorubicina
• Dinutuximab
• Doxorubicina <60 mg/m2
• Epirubicina <90 mg/m2
• Idarubicin
• Ifosfamidea <2 g/m2 per
dose
• Interferon-alfa ≥10 million
IU/m2
• Irinotecana
• Melphalan
• Methotrexatea
≥250 mg/m2
• Oxaliplatin
• Temozolomide
• Trabectedin
aMay be highly emetogenic in some patients.
NK-1 receptor antagonist as well as a 5-HT3 receptor antagonist
and dexamethasone (MASCC/ESMO, 2016).
It should be noted that emetogenic categories are based only
on the incidence of acute CINV, rather than delayed or overall
CINV. Indeed, one recent study found that the chemotherapy
regimen is an inconsistent predictor of CINV in the delayed phase
(Jordan et al., 2014). This suggests that emetogenic classifications
may not be the most appropriate determinant of prophylactic
antiemetic regimen for delayed CINV and may contribute to
undertreatment of delayed CINV due to a lack of appreciation
of the true emetogenic risk of particular types of chemotherapy.
Epidemiology and Risk Factors for
Delayed CINV
Chemotherapy-induced nausea and vomiting may be more
problematic during the delayed phase than the acute phase in
patients receiving HEC and MEC (Grunberg et al., 2004; Escobar
et al., 2015; Hsieh et al., 2015; Baba et al., 2016). For example,
in an international, prospective observational study of 298 adult
patients receiving chemotherapy for the first time, delayed nausea
and vomiting were observed in 60 and 50% of HEC patients,
respectively, and in 52 and 28% of MEC patients, respectively
(Grunberg et al., 2004), whereas acute nausea and vomiting
were seen in 12 and 33% of HEC patients, respectively, and
in 13 and 37% of MEC patients, respectively. The majority
of patients were receiving antiemetic prophylaxis according to
then-current guidelines, with 97% receiving a 5-HT3 receptor
antagonist and 78% a corticosteroid. The study concluded that
patients who do not experience acute CINV are not necessarily
protected from delayed CINV: 24 and 23% of patients reported
delayed nausea and emesis, respectively, even in the absence of
these events in the acute phase. Similar patterns were observed
among patients assigned to HEC and MEC. In another study
in 240 chemotherapy-naive patients in Spain who received
MEC with a 5-HT3 receptor antagonist plus corticosteroid
antiemetic prophylaxis, the incidence of CINV was higher in
the delayed phase than in the acute phase (Escobar et al., 2015).
This difference was statistically significant for the endpoints of
vomiting, nausea, and significant nausea, with rates increasing
from 9.2 to 16.5% (p= 0.0112), from 23.3 to 38.5% (p < 0.0001),
and from 9.4 to 21.7% (p = 0.0002), respectively. Twice as
many patients required rescue antiemetics (metoclopramide or
ondansetron) during the delayed phase (14.5%) as during the
acute phase (7.2%).
More recent observational studies continue to show that
delayed CINV may be incompletely controlled even if acute
CINV is adequately managed (Molassiotis et al., 2014; Hsieh
et al., 2015). In a large, heterogeneous group of European cancer
patients (n = 991) receiving their first cycle of routine HEC or
MEC, complete response (CR) rates (the proportion of patients
without vomiting or significant nausea) were 72% in the acute
phase and 62% in the delayed phase (Jordan et al., 2014). The
delayed-phase CR rate increased to 67% by cycle 3 (p = 0.0144
compared with cycle 1); this improvement seemed to be driven by
patients reporting no vomiting (71% in cycle 1 and 78% in cycle
3; p < 0.0001) rather than those reporting no significant nausea
(81% in cycle 1 and 81% in cycle 3).
Survey data indicates that oncologists and oncology nurses
can accurately predict the incidence of acute CINV after HEC;
however, the incidence of delayed CINV after HEC is often
underestimated. In one study, the predicted incidence of delayed
nausea was 39% (95% confidence interval [CI] 30–48%), whereas
the observed incidence was 60% (95% CI 48–72%), and the
predicted incidence of delayed vomiting was 22% (95% CI 12–
31%), whereas the observed incidence was 50% (95% CI 37–
63%) (Grunberg et al., 2004). Delayed CINV has also been
underestimated in patients receiving MEC (Grunberg et al., 2004;
Escobar et al., 2015). Misperceptions regarding the incidence of
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delayed CINV may have implications for treatment. For example,
in a hospital-based study in Spain, patients who experienced
acute vomiting in cycle 1 were significantly more likely to have
a change in antiemetic therapy in subsequent cycles; by contrast,
delayed vomiting or nausea at any stage did not lead to changes
in subsequent antiemetic regimens (Molassiotis et al., 2008).
Identifying which patients are at greatest risk for CINV is
a complex analysis combining clinical, personal, demographic,
and behavioral characteristics. A number of factors have been
identified that increase susceptibility to CINV, including female
sex, age <55 years, a history of nausea/vomiting, anxiety,
fatigue or motion sickness, impaired quality of life, and limited
alcohol use (Dranitsaris et al., 2013; Jordan et al., 2014). One
study evaluated independent risk factors for the development
of delayed CINV during cycle 1 of chemotherapy, identifying
guideline-inconsistent CINV prophylaxis, no use of secondary
antiemetics for delayed CINV, a history of nausea/vomiting,
and prechemotherapy (anticipatory) nausea (Jordan et al., 2014).
Other factors that have been associated with delayed CINV
include a history of motion sickness, acute CINV, and the use of
cisplatin (Kottschade et al., 2016). A small prospective study of
56 cancer patients (Higgins et al., 2007) also noted a significant
relationship between pretreatment distress and the severity of
subsequent delayed nausea but not acute nausea.
Studies evaluating multiple cycles of chemotherapy have
revealed that an important predictor of CINV in a given cycle
is whether CINV occurred in a previous cycle. A study of
patients from Italian oncology centers receiving ondansetron
or metoclopramide for cisplatin-associated CINV found that
protection from emesis during the first cycle of cisplatin-based
chemotherapy was an important predictor of protection in
subsequent cycles (Italian Group for Antiemetic Research, 1994).
Jordan et al. (2014) showed that the most significant independent
risk factor for delayed CINV during cycles 2 and 3 was not
achieving a CR in the previous cycle: patients without a CR in
the earlier cycle were 5.7–7.3 times more likely to have no CR
during the delayed phase in the subsequent cycle. Furthermore,
the failure to protect against delayed CINV in the first cycle
of chemotherapy can impair protection against acute CINV in
subsequent cycles (Ellebaek and Herrstedt, 2008). These findings
underscore the importance of effective management of delayed
CINV during the first cycle of chemotherapy.
Clinical Implications of Delayed CINV
Delayed CINV has a significant detrimental effect on a patient’s
daily life (Bloechl-Daum et al., 2006; Hilarius et al., 2012;
Grassi et al., 2015), even in the absence of acute CINV. In a
representative sample of 298 treatment-naive patients receiving
HEC or MEC and given CINV prophylaxis under then-current
patterns of clinical practice, the impact of CINV on daily life was
assessed using the Functional Living Index–Emesis questionnaire
on day 6 of cycle 1 (Bloechl-Daum et al., 2006). Only 32%
of patients who experienced delayed vomiting without acute
vomiting reported that CINV had no or minimal impact on daily
life, similar to the proportion of patients who experienced only
acute vomiting (30%). In the same study, 80% of patients who
experienced acute nausea without delayed nausea reported that
emesis did not affect their daily life; by contrast, only 56% of those
who experienced delayed nausea without acute nausea reported
no or minimal impact.
Delayed CINV is also responsible for significant healthcare
resource utilization (Ihbe-Heffinger et al., 2004; Burke et al.,
2011). In a United States–based retrospective cohort study that
included 19,139 patients receiving HEC or MEC, 13.7% of
patients had a delayed CINV-associated hospital visit and 0.2%
had an acute CINV-associated hospital visit (Burke et al., 2011).
CINV-associated visits included inpatient (64%), outpatient
(26%), and emergency room (<1%) visits.
PREVENTION OF DELAYED EMESIS
NK-1 Receptor Antagonists
The growing understanding of the role of substance P in
emesis led to the development of NK-1 receptor antagonists
for the treatment of delayed CINV. The first oral NK-
1 receptor antagonist, aprepitant, was approved in 2003,
followed by fosaprepitant (a prodrug of aprepitant that is
administered intravenously), netupitant (administered as a
fixed oral combination with the 5-HT3 receptor antagonist
palonosetron), and rolapitant. The efficacy and tolerability of NK-
1 receptor antagonists for prevention of delayed CINV when
used in combination with a 5-HT3 receptor antagonist and a
corticosteroid has been established in a number of randomized
controlled trials, as described below. The findings of these
trials, along with the demonstrated inability of 5-HT3 receptor
antagonists to prevent delayed CINV (Aapro, 2005), show the
need to incorporate NK-1 receptor antagonists in the treatment
of delayed CINV.
The addition of aprepitant to ondansetron plus dexa-
methasone was shown to increase protection against delayed
CINV in patients receiving HEC (Hesketh et al., 2003; Poli-
Bigelli et al., 2003) and MEC (Rapoport et al., 2010). In a
phase 3, randomized, double-blind study in patients scheduled
to receive treatment with high-dose cisplatin, CR rates during
the delayed phase were 68% in the aprepitant group and 47% in
the standard-therapy group (p < 0.001) (Poli-Bigelli et al., 2003).
While aprepitant was associated with a significant improvement
in the proportion of patients who did not experience delayed
vomiting (72 vs. 48%; p < 0.01), between-treatment differences
in rates of no significant nausea (73 vs. 65%) were not statistically
significant. In a similar study, CR rates during the delayed phase
were 66% in the aprepitant group and 52% in the standard-
therapy group (p < 0.001) (Hesketh et al., 2003). As in the
previous study, aprepitant had a significant benefit with respect
to rates of emesis but not nausea. Benefits on delayed CINV
were also reported in patients treated with MEC (including AC
regimens) (Rapoport et al., 2010).
Single-dose fosaprepitant was approved for use in delayed
CINV based on the results of a phase 3 non-inferiority trial
versus aprepitant (administered once daily for 3 days) in patients
receiving HEC and treated with background ondansetron and
dexamethasone (Grunberg et al., 2011). No significant difference
was reported between the fosaprepitant and aprepitant arms
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with regard to CR rate in the delayed phase (74.3 vs. 76.8%).
A recent phase 3 study evaluated the addition of fosaprepitant
to ondansetron and dexamethasone in patients receiving non-AC
MEC (Weinstein et al., 2016). In this randomized, double-blind,
placebo-controlled study, fosaprepitant significantly improved
rates of delayed CR (79 vs. 69%; p < 0.001) and no emesis (84
vs. 75%; p< 0.001). The impact of fosaprepitant on nausea in the
delayed phase of this study was not described.
In 2014, netupitant was approved for prevention of CINV.
Netupitant is administered as a fixed oral combination with
palonosetron (NEPA), and this formulation has been evaluated in
phase 3 randomized controlled trials in patients receiving HEC
(Hesketh et al., 2014) and AC (considered MEC at the time of
the study) (Aapro et al., 2014c). In the HEC population, a CR
during the delayed phase was reported in 92% of the NEPA
plus dexamethasone group compared with 80% of the control
group receiving palonosetron plus dexamethasone (p ≤ 0.01),
with significant benefits reported in terms of both vomiting and
nausea (Hesketh et al., 2014). In the AC study, the percentage
of patients with a CR during the delayed phase was significantly
higher with NEPA plus dexamethasone than with palonosetron
plus dexamethasone (76.9 vs. 69.5%; p = 0.0001) (Aapro et al.,
2014c). Likewise, NEPA plus dexamethasone was associated with
significantly higher rates of no emesis (81.8 vs. 75.6%; p= 0.004)
and no significant nausea (defined as a reading of <25 mm
on a 100-mm horizontal visual analog scale) (76.9 vs. 71.3%;
p= 0.014).
Rolapitant is the most recent NK-1 receptor antagonist to
be approved, and it is licensed for the treatment of delayed
CINV associated with initial and repeat courses of emetogenic
chemotherapy including, but not limited to, HEC (Varubi, 2015).
The efficacy of rolapitant in preventing CINV when added to
granisetron plus dexamethasone has been evaluated in two phase
3 clinical trials in patients receiving HEC (Rapoport B.L. et al.,
2015) and one phase 3 clinical trial in patients receiving MEC
or AC-based chemotherapy (Schwartzberg L.S. et al., 2015). In
a pooled analysis of the HEC studies, the addition of rolapitant to
active therapy resulted in a 60% improvement in the likelihood of
achieving a CR in the delayed phase (71% of rolapitant recipients
vs. 60% of active-control recipients; odds ratio 1.6; 95% CI 1.3–
2.1; p = 0.0001) (Rapoport B.L. et al., 2015). The addition of
rolapitant to active therapy also produced a significantly higher
rate of no emesis and no clinically significant nausea in the
delayed phase.
In the MEC study, rolapitant recipients had a higher rate
of CR in the delayed phase than active-control recipients (71
vs. 62%; OR 1.6; 95% CI 1.2–2.0; p = 0.0002), and rolapitant
was associated with significant benefits in the prevention of
vomiting but not of nausea. A prespecified analysis found that
the benefit of rolapitant on CR in the delayed phase was
maintained irrespective of whether patients were treated with
AC. A further analysis in the subgroup of patients treated with
carboplatin-based chemotherapy found that the absolute benefit
observed with rolapitant (the absolute difference between the
proportion of rolapitant and active-control respondents) was
16.7 percentage points for CR in the delayed phase (Hesketh
et al., 2016b). Interestingly, in the study mentioned above that
showed improved rates of delayed-phase CR and delayed-phase
emesis with fosaprepitant in patients receiving non-AC MEC,
approximately 53% of these patients were receiving a carboplatin-
based chemotherapy regimen (Weinstein et al., 2016). While this
study did not stratify efficacy findings by individual MEC agent,
it does support the use of NK-1–receptor antagonists in patients
receiving carboplatin. This is borne out in the recent update
to the MASCC/ESMO guidelines, in which an NK-1 receptor
antagonist is recommended in addition to a 5-HT3 receptor
antagonist and dexamethasone for patients receiving carboplatin
(MASCC/ESMO, 2016).
In the trials of rolapitant for the treatment of CINV associated
with HEC, more patients receiving rolapitant than active control
reported no nausea (≤5 mm on a 100-mm horizontal visual
analog scale) in both the overall phase (52 vs. 42%, p = 0.0004)
and the delayed phase (56 vs. 44%; p = 0.0002) (Rapoport B.L.
et al., 2015). In one of the trials of aprepitant in patients receiving
cisplatin, a greater proportion of patients in the aprepitant group
than in the active-control group reported no nausea in the
overall phase (49 vs. 39%; p < 0.005) and the delayed phase
(53 vs. 40%, p < 0.05) (Poli-Bigelli et al., 2003), but these
effects were not replicated in the second concurrent aprepitant
trial in cisplatin-treated patients (Hesketh et al., 2003). Neither
rolapitant, aprepitant, nor fosaprepitant significantly increased
the number of patients reporting no nausea after treatment
with MEC (Rapoport et al., 2010; Schwartzberg L.S. et al., 2015;
Weinstein et al., 2016). Trials of NEPA did not include no nausea
as an endpoint measure (Aapro et al., 2014c; Hesketh et al., 2014).
Three studies have been published describing the efficacy and
safety of aprepitant over multiple cycles of chemotherapy. The
first assessed the use of aprepitant over six cycles of cisplatin
treatment, using transitional probability models to estimate
response rates; it showed that the probability of a CR (no emesis
and no significant nausea) was greater in patients receiving
aprepitant than active control in the first, fifth, and sixth cisplatin
treatment cycles (p < 0.05) (de Wit et al., 2003), with drug-
related adverse events (AEs) reported in 34% of patients receiving
aprepitant versus 25% of those receiving standard therapy.
A much larger pooled analysis of the two aforementioned phase
3 trials (Hesketh et al., 2003; Poli-Bigelli et al., 2003), also using
transitional probability analyses, found that aprepitant-treated
patients were more likely than those receiving standard therapy
to exhibit a CR over all six cycles of cisplatin-based therapy (de
Wit et al., 2004), with similar rates of drug-related AEs (6 and
4%, respectively). Aprepitant treatment was also associated with
a greater probability of CR in each treatment cycle in patients
receiving four cycles of MEC (Herrstedt et al., 2005); overall rates
of drug-related AEs were not reported.
In a multiple-cycle extension of the phase 3 trial reported
by Aapro et al. (2014c), NEPA was associated with superior CR
rates compared with palonosetron over four cycles of AC-based
chemotherapy (p < 0.001 in cycles 2–4), with a similar incidence
of AEs observed in each treatment arm (Aapro et al., 2014b). The
efficacy and safety of NEPA versus aprepitant over six cycles of
chemotherapy in patients receiving MEC or HEC was evaluated
in a phase 3 clinical trial (Gralla et al., 2014); overall rates of CR
in each cycle were similar for the two treatments (81–91% and
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76–88%, respectively), and rates of drug-related AEs were also
similar over all cycles (10 and 6%, respectively).
To determine the efficacy and safety of rolapitant over multiple
cycles of chemotherapy, a post hoc analysis was carried out
on pooled safety and efficacy data from four rolapitant clinical
studies (Rapoport et al., 2016): the phase 2 dose-determining
study of rolapitant in patients receiving HEC (Rapoport B.
et al., 2015) and the three previously mentioned phase 3 trials
(Rapoport B.L. et al., 2015; Schwartzberg L.S. et al., 2015). Rates of
emesis were lower in the pooled population of patients receiving
rolapitant than in those receiving placebo in all chemotherapy
cycles after the first (cycles 2–6), and a higher proportion of
patients in the pooled rolapitant group reported no nausea
interfering with daily life and the combined measure of no emesis
or interfering nausea over cycles 2–5 (Rapoport et al., 2016). The
incidence of treatment-emergent AEs was low and was similar in
both groups after cycle 1 (rolapitant, 5.5%; control, 6.8%), and it
did not increase with each subsequent cycle.
NK-1 receptor antagonists are generally well tolerated;
the most commonly reported treatment-emergent AEs with
NK-1 receptor antagonists in clinical trials included headache,
constipation, fatigue, and hiccups, which appeared with a similar
frequency as in active-control groups (Navari, 2016).
Differences in pharmacokinetic properties between NK-1
receptor antagonists may affect their dosing (Table 2). Aprepitant
has a relatively short half-life of 9–13 h, requiring daily dosing
across days 1–3 of each cycle (Emend, 2015), whereas the
half-lives for NEPA and rolapitant are approximately 80 and
180 h, respectively, and each agent is administered as a single
dose 1–2 h prior to chemotherapy (Akynzeo, 2015; Varubi,
2015). All of the NK-1 receptor antagonists, with the exception
of rolapitant, inhibit or induce CYP3A4. A reduced dose of
dexamethasone (a CYP3A4 substrate) should be administered
with aprepitant and NEPA, but it is not required with
rolapitant. Rolapitant does not inhibit or induce CYP3A4,
with no effect shown on the pharmacokinetics of the sensitive
CYP3A4 substrate midazolam (Poma et al., 2013). Rolapitant
is a moderate inhibitor of CYP2D6 and an inhibitor of
breast cancer resistance protein (BCRP) and P-glycoprotein,
and its concomitant use with substrates of these enzymes
that have a narrow therapeutic index should be avoided.
TABLE 2 | Recommended dosing of NK-1 receptor antagonists.
NK-1 receptor antagonist Day 1 Days 2–3
Aprepitant Single oral 125-mg
dose prior to
chemotherapy
Oral dose of 80 mg
once daily on days 2
and 3
Fosaprepitant Single intravenous
150-mg dose prior to
chemotherapy
–
Netupitant Single oral 300 mg
netupitant/0.5-mg
palonosetron dose prior
to chemotherapy
–
Rolapitant Single oral 180-mg
dose prior to
chemotherapy
–
However, in an integrated safety analysis of randomized trials,
the incidence of treatment-emergent AEs was similar in the
rolapitant and control arms in patients who used concomitant
CYP2D6, BCRP, or CYP3A4 substrate drugs (Barbour et al.,
2015).
Other Antiemetics for Delayed Emesis
Corticosteroids have been used as prophylaxis against CINV,
particularly delayed CINV, for many years, although their exact
mechanism of action is unknown. The antiemetic efficacy of
5-HT3 receptor antagonists (or dopamine antagonists) increases
when they are used in combination with corticosteroids
(Grunberg, 2007); therefore, these agents are typically
administered concurrently.
Olanzapine, an atypical antipsychotic drug that blocks
dopaminergic, serotonergic, adrenergic, and histamine receptors,
has been evaluated in combination with 5-HT3 receptor
antagonist and corticosteroid for delayed CINV prophylaxis
(Tan et al., 2009; Navari et al., 2011). Benefits with this
agent have been reported for both acute and delayed nausea
control (Abe et al., 2016; Chiu et al., 2016; Navari et al.,
2016). The National Comprehensive Cancer Network (2016)
guidelines include olanzapine with a 5-HT3 antagonist and
corticosteroid as a treatment option for prevention of both
HEC- and MEC-associated CINV. The recommendations also
include consideration of replacing NK-1 receptor antagonist–
containing regimens with an olanzapine-containing regimen for
management of breakthrough emesis.
CURRENT CINV PROPHYLAXIS
GUIDELINES
Several evidence-based guidelines for the prevention of
CINV have been developed by international professional
societies (Hesketh et al., 2016b; MASCC/ESMO, 2016; National
Comprehensive Cancer Network, 2016), which are relatively
consistent in their key recommendations (summarized in
Table 3). In general, the guidelines recommend prescribing
a NK-1 receptor antagonist along with a 5-HT3 receptor
antagonist and dexamethasone for prevention of CINV in
patients receiving HEC, and a 5-HT3 receptor antagonist
and dexamethasone in patients receiving MEC (Hesketh
et al., 2016b; MASCC/ESMO, 2016; National Comprehensive
Cancer Network, 2016). The National Comprehensive Cancer
Network and the American Society of Clinical Oncology
also recommend that an NK-1 receptor antagonist be
considered for patients treated with MEC, particularly those with
additional risk factors for CINV (Hesketh et al., 2016b; National
Comprehensive Cancer Network, 2016). The authors of these
guidelines have made a concerted effort to define antiemetic
regimens that cover both the acute and delayed phases of
CINV.
Adherence to antiemetic guidelines improves the control of
acute and delayed CINV (Aapro et al., 2012); however, such
adherence is suboptimal across a range of settings (Aapro et al.,
2012; Burmeister et al., 2012; Gomez et al., 2013; Gilmore
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TABLE 3 | Summary of evidence-based guidelines for
chemotherapy-induced nausea and vomiting (CINV) prophylaxis with
intravenous chemotherapy.
Emetic risk category Guideline recommendation
High (including AC combinations) NK-1 receptor antagonist + 5-HT3 receptor
antagonist + dexamethasone (Hesketh et al.,
2016b; MASCC/ESMO, 2016; National
Comprehensive Cancer Network, 2016)
or
Olanzapine + 5-HT3 receptor antagonist +
dexamethasone (National Comprehensive
Cancer Network, 2016)
Moderate 5-HT3 receptor antagonist + dexamethasone
( ± NK-1 receptor antagonista) (Basch et al.,
2011; National Comprehensive Cancer
Network, 2016)
or
Olanzapine + 5-HT3 receptor antagonist +
dexamethasone (National Comprehensive
Cancer Network, 2016)
or
5-HT3 receptor antagonist + dexamethasone
(MASCC/ESMO, 2016)
Low Dexamethasone (Basch et al., 2011;
MASCC/ESMO, 2016; National Comprehensive
Cancer Network, 2016)
or
Dopamine receptor antagonist OR 5-HT3
receptor antagonist (MASCC/ESMO, 2016;
National Comprehensive Cancer Network,
2016)
Minimal No prophylactic antiemetic (Basch et al., 2011;
MASCC/ESMO, 2016; National Comprehensive
Cancer Network, 2016)
aAn NK-1 receptor antagonist should be added for patients with additional
risk factors or who are failing 5-HT3 receptor antagonist + dexamethasone
(National Comprehensive Cancer Network, 2016). The NK-1 receptor antagonist
recommended in the ASCO guidelines is aprepitant (Basch et al., 2011).
5-HT3, 5-hydroxytryptamine type 3; AC, anthracycline–cyclophosphamide; CINV,
chemotherapy-induced nausea and vomiting; NK-1, neurokinin-1.
et al., 2014; Jordan et al., 2014; Yu et al., 2015). Nonadherence
to guidelines may include the failure to use NK-1 receptor
antagonists as part of the antiemetic regimen (Gomez et al.,
2013; Gilmore et al., 2014) and the overuse of 5-HT3 receptor
antagonists for prevention of delayed CINV (Burmeister et al.,
2012).
CONCLUSION AND FUTURE
DIRECTIONS
At present, antiemetic therapy recommendations are based
largely on the emetogenic potential of the chemotherapy regimen,
with less consideration of individual risk factors. Incorporation
of personal risk factors may allow better prediction of CINV
and improve personalized management of CINV. Indices that
can discriminate between patients at high and low risk of
both acute and delayed CINV are currently in development
(Dranitsaris et al., 2013) and are being validated in randomized
controlled trials. For example, patients with early-stage breast
cancer receiving AC were randomized to risk-model guided
(RMG) antiemetic prophylaxis or physician’s choice of therapy.
Benefits were seen in both the acute and delayed phase with RMG
therapy: specifically, significantly more patients in the RMG
group than the physician’s choice group reported no delayed
nausea (39.6 vs. 30.7%; p = 0.01) and no delayed vomiting (87.1
vs. 78.0%; p < 0.001) (Clemons et al., 2016). The development
of algorithms with high sensitivity and specificity to aid clinical
decision making may improve CINV prophylaxis, particularly in
the delayed phase.
There are several possible explanations for the persistence of
delayed CINV even in the absence of acute CINV. The delayed
phase may be inherently resistant to treatment, appropriate
prophylactic antiemetics may be inadequately prescribed because
of underestimation of delayed CINV control, or patients may
be nonadherent to prescribing instructions when pills need
to be taken at home. Whatever the case, delayed CINV
continues to be a treatment challenge. Effective treatment
of nausea over both the acute and delayed phases also
remains an unmet clinical need in both patients receiving
HEC and those receiving MEC (Ng et al., 2015), although
the addition of olanzapine to standard triple therapy of
an NK-1 receptor antagonist, a 5-HT3 receptor antagonist,
and dexamethasone has shown benefit in patients receiving
cisplatin- or cyclophosphamide-doxorubicin–based HEC (Abe
et al., 2016; Chiu et al., 2016; Navari et al., 2016). Identifying
patients at risk of delayed CINV and initiating prophylaxis
with triple therapy before administration of chemotherapy
is likely to improve clinical outcomes and patients’ daily
lives.
AUTHOR CONTRIBUTIONS
BLR developed the concept of this work, critically revised all
drafts, gave final approval for submission of the final version for
publication, and is accountable for all aspects of the work.
FUNDING
Analysis, writing, and editorial support for this work were fully
funded by Tesaro.
ACKNOWLEDGMENTS
Hannah Mace, MPharmacol, and Jeremy Kennard, PhD (Ashfield
Healthcare Communications, Middletown, CT, USA), drafted
and revised the manuscript based on input from the author,
and Joshua Safran (Ashfield Healthcare Communications)
copyedited and styled the manuscript per journal
requirements.
Frontiers in Pharmacology | www.frontiersin.org 7 January 2017 | Volume 8 | Article 19
fphar-08-00019 January 27, 2017 Time: 16:55 # 8
Rapoport Delayed CINV: Pathogenesis, Incidence, Management
REFERENCES
Aapro, M. (2005). 5-HT(3)-receptor antagonists in the management of nausea and
vomiting in cancer and cancer treatment. Oncology 69, 97–109. doi: 10.1159/
000087979
Aapro, M., Jordan, K., and Feyer, P. (2014a). Prevention of Nausea and Vomiting
in Adult Cancer Patients Receiving Tumour-Directed Therapy. Amsterdam:
Elsevier.
Aapro, M., Karthaus, M., Schwartzberg, L., Rossi, G., Rizzi, G., Borroni, M. E., et al.
(2014b). Phase 3 study of NEPA, a fixed-dose combination of netupitant and
palonosetron, for prevention of chemotherapy-induced nausea and vomiting
during repeated moderately emetogenic chemotherapy (MEC) cycles. J. Clin.
Oncol. 32, 5s.
Aapro, M., Molassiotis, A., Dicato, M., Pelaez, I., Rodriguez-Lescure, A.,
Pastorelli, D., et al. (2012). The effect of guideline-consistent antiemetic therapy
on chemotherapy-induced nausea and vomiting (CINV): the Pan European
Emesis Registry (PEER). Ann. Oncol. 23, 1986–1992. doi: 10.1093/annonc/
mds021
Aapro, M., Rugo, H., Rossi, G., Rizzi, G., Borroni, M. E., Bondarenko, I.,
et al. (2014c). A randomized phase III study evaluating the efficacy and
safety of NEPA, a fixed-dose combination of netupitant and palonosetron,
for prevention of chemotherapy-induced nausea and vomiting following
moderately emetogenic chemotherapy. Ann. Oncol. 25, 1328–1333. doi: 10.
1093/annonc/mdu101
Abe, M., Hirashima, Y., Kasamatsu, Y., Kado, N., Komeda, S., Kuji, S., et al. (2016).
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and
dexamethasone for preventing nausea and vomiting induced by cisplatin-based
chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support
Care Cancer 24, 675–682. doi: 10.1007/s00520-015-2829-z
Akynzeo (2015). Woodcliff Lake, NJ: Eisai Inc. Available at: https://www.akynzeo.
com/assets/pdf/Prescribing_Information.pdf [Accessed 25th October, 2016].
Armstrong, D. M., Pickel, V. M., Joh, T. H., Reis, D. J., and Miller, R. J. (1981).
Immunocytochemical localization of catecholamine synthesizing enzymes and
neuropeptides in area postrema and medial nucleus tractus solitarius of rat
brain. J. Comp. Neurol. 196, 505–517. doi: 10.1002/cne.901960312
Baba, Y., Baba, H., Yamamoto, S., Shimada, H., Shibata, T., Miyazaki, T., et al.
(2016). Chemotherapy-induced nausea and vomiting is less controlled at
delayed phase in patients with esophageal cancer: a prospective registration
study by the CINV Study Group of Japan. Dis. Esophagus doi: 10.1111/dote.
12482 [Epub ahead of print].
Babic, T., and Browning, K. N. (2014). The role of vagal neurocircuits in the
regulation of nausea and vomiting. Eur. J. Pharmacol 722, 38–47. doi: 10.1016/
j.ejphar.2013.08.047
Barbour, S., Wang, X., Poma, A., Arora, S., Aapro, M., and Herrstedt, J. (2015). 1529
Low risk of drug interactions when rolapitant is coadministered with CYP2D6
or BCRP substrates: Integrated safety results. Eur. J. Cancer 51(Suppl. 3), S214.
doi: 10.1016/S0959-8049(16)30619-0
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield,
M. R., et al. (2011). Antiemetics: American Society of Clinical Oncology clinical
practice guideline update. J. Clin. Oncol. 29, 4189–4198. doi: 10.1200/JCO.2010.
34.4614
Bloechl-Daum, B., Deuson, R. R., Mavros, P., Hansen, M., and Herrstedt, J. (2006).
Delayed nausea and vomiting continue to reduce patients’ quality of life after
highly and moderately emetogenic chemotherapy despite antiemetic treatment.
J. Clin. Oncol. 24, 4472–4478. doi: 10.1200/JCO.2006.05.6382
Burke, T. A., Wisniewski, T., and Ernst, F. R. (2011). Resource utilization and
costs associated with chemotherapy-induced nausea and vomiting (CINV)
following highly or moderately emetogenic chemotherapy administered in the
US outpatient hospital setting. Support Care Cancer 19, 131–140. doi: 10.1007/
s00520-009-0797-x
Burmeister, H., Aebi, S., Studer, C., Fey, M. F., and Gautschi, O. (2012). Adherence
to ESMO clinical recommendations for prophylaxis of chemotherapy-induced
nausea and vomiting. Support Care Cancer 20, 141–147. doi: 10.1007/s00520-
010-1079-3
Chiu, L., Chow, R., Popovic, M., Navari, R. M., Shumway, N. M., Chiu, N., et al.
(2016). Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-
induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Support Care Cancer 24, 2381–2392. doi: 10.1007/s00520-016-3075-8
Clemons, M., Bouganim, N., Smith, S., Mazzarello, S., Vandermeer, L., Segal, R.,
et al. (2016). Risk model-guided antiemetic prophylaxis vs physician’s choice
in patients receiving chemotherapy for early-stage breast cancer: a randomized
clinical trial. JAMA Oncol. 2, 225–231. doi: 10.1001/jamaoncol.2015.3730
de Boer-Dennert, M., De Wit, R., Schmitz, P. I, Djontono, J. V., Beurden, V.,
Stoter, G., et al. (1997). Patient perceptions of the side-effects of chemotherapy:
the influence of 5HT3 antagonists. Br. J. Cancer 76, 1055–1061. doi: 10.1038/
bjc.1997.507
de Wit, R., Herrstedt, J., Rapoport, B., Carides, A. D., Carides, G., Elmer, M., et al.
(2003). Addition of the oral NK1 antagonist aprepitant to standard antiemetics
provides protection against nausea and vomiting during multiple cycles of
cisplatin-based chemotherapy. J. Clin. Oncol. 21, 4105–4111. doi: 10.1200/JCO.
2003.10.128
de Wit, R., Herrstedt, J., Rapoport, B., Carides, A. D., Guoguang-Ma, J.,
Elmer, M., et al. (2004). The oral NK(1) antagonist, aprepitant, given with
standard antiemetics provides protection against nausea and vomiting over
multiple cycles of cisplatin-based chemotherapy: a combined analysis of two
randomised, placebo-controlled phase III clinical trials. Eur. J. Cancer 40,
403–410. doi: 10.1016/S0959-8049(03)00931-6
Dranitsaris, G., Bouganim, N., Milano, C., Vandermeer, L., Dent, S., Wheatley-
Price, P., et al. (2013). Prospective validation of a prediction tool for identifying
patients at high risk for chemotherapy-induced nausea and vomiting. J. Support
Oncol. 11, 14–21.
Ellebaek, E., and Herrstedt, J. (2008). Optimizing antiemetic therapy in multiple-
day and multiple cycles of chemotherapy. Curr. Opin. Support Palliat Care 2,
28–34. doi: 10.1097/SPC.0b013e3282f44a75
Emend (2015). Whitehouse, NJ: Merck Sharp & Dohme Corp. Available at: https:
//www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf [Accessed
25th October, 2016].
Escobar, Y., Cajaraville, G., Virizuela, J. A., Alvarez, R., Munoz, A., Olariaga, O.,
et al. (2015). Incidence of chemotherapy-induced nausea and vomiting with
moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting
Incidence by Chemotherapy Evaluation) study. Support Care Cancer 23,
2833–2840. doi: 10.1007/s00520-015-2809-3
Garcia-Recio, S., and Gascon, P. (2015). Biological and pharmacological aspects of
the NK1-receptor. Biomed. Res. Int. 2015, 495704. doi: 10.1155/2015/495704
Gilmore, J. W., Peacock, N. W., Gu, A., Szabo, S., Rammage, M., Sharpe, J.,
et al. (2014). Antiemetic guideline consistency and incidence of chemotherapy-
induced nausea and vomiting in US community oncology practice: INSPIRE
Study. J. Oncol. Pract. 10, 68–74. doi: 10.1200/JOP.2012.000816
Gomez, D. R., Liao, K. P., Giordano, S., Nguyen, H., Smith, B. D., and Elting, L. S.
(2013). Adherence to national guidelines for antiemesis prophylaxis in patients
undergoing chemotherapy for lung cancer: a population-based study. Cancer
119, 1428–1436. doi: 10.1002/cncr.27899
Gralla, R. J., Bosnjak, S. M., Hontsa, A., Balser, C., Rizzi, G., Rossi, G., et al. (2014).
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose
combination of netupitant and palonosetron, for prevention of chemotherapy-
induced nausea and vomiting over repeated cycles of chemotherapy. Ann.
Oncol. 25, 1333–1339. doi: 10.1093/annonc/mdu096
Grassi, L., Berardi, M. A., Ruffilli, F., Meggiolaro, E., Andritsch, E., Sirgo, A., et al.
(2015). Role of psychosocial variables on chemotherapy-induced nausea and
vomiting and health-related quality of life among cancer patients: a European
study. Psychother. Psychosom. 84, 339–347. doi: 10.1159/000431256
Grunberg, S., Chua, D., Maru, A., Dinis, J., Devandry, S., Boice, J. A., et al. (2011).
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea
and vomiting associated with cisplatin therapy: randomized, double-blind study
protocol–EASE. J. Clin. Oncol. 29, 1495–1501. doi: 10.1200/JCO.2010.31.7859
Grunberg, S. M. (2007). Antiemetic activity of corticosteroids in patients receiving
cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann. Oncol. 18,
233–240. doi: 10.1093/annonc/mdl347
Grunberg, S. M., Deuson, R. R., Mavros, P., Geling, O., Hansen, M., Cruciani, G.,
et al. (2004). Incidence of chemotherapy-induced nausea and emesis after
modern antiemetics. Cancer 100, 2261–2268. doi: 10.1002/cncr.20230
Herrstedt, J., Muss, H. B., Warr, D. G., Hesketh, P. J., Eisenberg, P. D.,
Raftopoulos, H., et al. (2005). Efficacy and tolerability of aprepitant for the
prevention of chemotherapy-induced nausea and emesis over multiple cycles
of moderately emetogenic chemotherapy. Cancer 104, 1548–1555. doi: 10.1002/
cncr.21343
Frontiers in Pharmacology | www.frontiersin.org 8 January 2017 | Volume 8 | Article 19
fphar-08-00019 January 27, 2017 Time: 16:55 # 9
Rapoport Delayed CINV: Pathogenesis, Incidence, Management
Hesketh, P. J. (2008). Chemotherapy-induced nausea and vomiting. N. Engl. J. Med.
358, 2482–2494. doi: 10.1056/NEJMra0706547
Hesketh, P. J., Bohlke, K., Lyman, G. H., Basch, E., Chesney, M., Clark-Snow, R. A.,
et al. (2016a). Antiemetics: American Society of Clinical Oncology focused
guideline update. J. Clin. Oncol. 34, 381–386. doi: 10.1200/JCO.2015.64.3635
Hesketh, P. J., Grunberg, S. M., Gralla, R. J., Warr, D. G., Roila, F., De Wit, R.,
et al. (2003). The oral neurokinin-1 antagonist aprepitant for the prevention
of chemotherapy-induced nausea and vomiting: a multinational, randomized,
double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–
the Aprepitant Protocol 052 Study Group. J. Clin. Oncol. 21, 4112–4119.
Hesketh, P. J., Kris, M. G., Grunberg, S. M., Beck, T., Hainsworth, J. D.,
Harker, G., et al. (1997). Proposal for classifying the acute emetogenicity of
cancer chemotherapy. J. Clin. Oncol. 15, 103–109.
Hesketh, P. J., Rossi, G., Rizzi, G., Palmas, M., Alyasova, A., Bondarenko, I., et al.
(2014). Efficacy and safety of NEPA, an oral combination of netupitant and
palonosetron, for prevention of chemotherapy-induced nausea and vomiting
following highly emetogenic chemotherapy: a randomized dose-ranging pivotal
study. Ann. Oncol. 25, 1340–1346. doi: 10.1093/annonc/mdu110
Hesketh, P. J., Schnadig, I. D., Schwartzberg, L. S., Modiano, M. R., Jordan, K.,
Arora, S., et al. (2016b). Efficacy of the neurokinin-1 receptor antagonist
rolapitant in preventing nausea and vomiting in patients receiving carboplatin-
based chemotherapy. Cancer 122, 2418–2425. doi: 10.1002/cncr.30054
Higgins, S. C., Montgomery, G. H., and Bovbjerg, D. H. (2007). Distress before
chemotherapy predicts delayed but not acute nausea. Support Care Cancer 15,
171–177. doi: 10.1007/s00520-006-0113-y
Hilarius, D. L., Kloeg, P. H., Van Der Wall, E., Van Den Heuvel, J. J., Gundy, C. M.,
and Aaronson, N. K. (2012). Chemotherapy-induced nausea and vomiting in
daily clinical practice: a community hospital-based study. Support Care Cancer
20, 107–117. doi: 10.1007/s00520-010-1073-9
Hsieh, R. K., Chan, A., Kim, H. K., Yu, S., Kim, J. G., Lee, M. A., et al. (2015).
Baseline patient characteristics, incidence of CINV, and physician perception of
CINV incidence following moderately and highly emetogenic chemotherapy in
Asia Pacific countries. Support Care Cancer 23, 263–272. doi: 10.1007/s00520-
014-2373-2
Ihbe-Heffinger, A., Ehlken, B., Bernard, R., Berger, K., Peschel, C., Eichler,
H. G., et al. (2004). The impact of delayed chemotherapy-induced nausea and
vomiting on patients, health resource utilization and costs in German cancer
centers. Ann. Oncol. 15, 526–536. doi: 10.1093/annonc/mdh110
Italian Group for Antiemetic Research. (1994). Cisplatin-induced delayed emesis:
pattern and prognostic factors during three subsequent cycles. Italian Group for
Antiemetic Research. Ann. Oncol. 5, 585–589.
Jordan, K., Gralla, R., Jahn, F., and Molassiotis, A. (2014). International antiemetic
guidelines on chemotherapy induced nausea and vomiting (CINV): content
and implementation in daily routine practice. Eur. J. Pharmacol. 722, 197–202.
doi: 10.1016/j.ejphar.2013.09.073
Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H. H., et al. (2007).
A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists
for acute chemotherapy-induced emesis. Support Care Cancer 15, 1023–1033.
doi: 10.1007/s00520-006-0186-7
Jordan, K., Jahn, F., and Aapro, M. (2015). Recent developments in the prevention
of chemotherapy-induced nausea and vomiting (CINV): a comprehensive
review. Ann. Oncol. 26, 1081–1090. doi: 10.1093/annonc/mdv138
Kottschade, L., Novotny, P., Lyss, A., Mazurczak, M., Loprinzi, C., and
Barton, D. (2016). Chemotherapy-induced nausea and vomiting: incidence and
characteristics of persistent symptoms and future directions NCCTG N08C3
(Alliance). Support Care Cancer 24, 2661–2667. doi: 10.1007/s00520-016-
3080-y
MASCC/ESMO (2016). Antiemetic Guideline 2016. Version 1.2. Available at:
http://www.mascc.org/assets/Guidelines_Tools/mascc_antiemetic_guidelines_
english_2016_v.1.2.pdf
Molassiotis, A., Aapro, M., Dicato, M., Gascon, P., Novoa, S. A., Isambert, N.,
et al. (2014). Evaluation of risk factors predicting chemotherapy-related nausea
and vomiting: results from a European prospective observational study. J. Pain
Symptom Manage. 47:e834. doi: 10.1016/j.jpainsymman.2013.06.012
Molassiotis, A., Saunders, M. P., Valle, J., Wilson, G., Lorigan, P., Wardley, A., et al.
(2008). A prospective observational study of chemotherapy-related nausea and
vomiting in routine practice in a UK cancer centre. Support Care Cancer 16,
201–208. doi: 10.1007/s00520-007-0343-7
National Comprehensive Cancer Network (2016). NCCN Clinical Practice
Guidelines in Oncology: Antiemesis. Version 1. 2016. Available at: www.nccn.org
Navari, R. M. (2016). The safety of antiemetic medications for the prevention of
chemotherapy-induced nausea and vomiting. Exp. Opin. Drug Saf. 15, 343–356.
doi: 10.1517/14740338.2016.1135899
Navari, R. M., and Aapro, M. (2016). Antiemetic prophylaxis for chemotherapy-
induced nausea and vomiting. N. Engl. J. Med. 374, 1356–1367. doi: 10.1056/
NEJMra1515442
Navari, R. M., Gray, S. E., and Kerr, A. C. (2011). Olanzapine versus aprepitant for
the prevention of chemotherapy-induced nausea and vomiting: a randomized
phase III trial. J. Support. Oncol. 9, 188–195. doi: 10.1016/j.suponc.2011.05.002
Navari, R. M., Qin, R., Ruddy, K. J., Liu, H., Powell, S. F., Bajaj, M., et al. (2016).
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
N. Engl. J. Med. 375, 134–142. doi: 10.1056/NEJMoa1515725
Ng, T. L., Hutton, B., and Clemons, M. (2015). Chemotherapy-induced nausea
and vomiting: time for more emphasis on nausea? Oncologist 20, 576–583.
doi: 10.1634/theoncologist.2014-0438
Poli-Bigelli, S., Rodrigues-Pereira, J., Carides, A. D., Julie Ma, G., Eldridge, K.,
Hipple, A., et al. (2003). Addition of the neurokinin 1 receptor antagonist
aprepitant to standard antiemetic therapy improves control of chemotherapy-
induced nausea and vomiting. Results from a randomized, double-blind,
placebo-controlled trial in Latin America. Cancer 97, 3090–3098. doi: 10.1002/
cncr.11433
Poma, A., Christensen, J., Pertikis, H., Arora, S., and Hedley, M. (2013). Rolapitant
and its major metabolite do not affect the pharmacokinetics of midazolam, a
sensitive cytochrome P450 3A4 substrate. Support Care Cancer 21:S154.
Rapoport, B., Chua, D., Poma, A., Arora, S., Wang, Y., and Fein, L. E. (2015).
Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the
prevention of chemotherapy-induced nausea and vomiting (CINV) due to
highly emetogenic chemotherapy (HEC). Support Care Cancer 23, 3281–3288.
doi: 10.1007/s00520-015-2738-1
Rapoport, B., Schwartzberg, L., Chasen, M., Powers, D., Arora, S., Navari, R.,
et al. (2016). Efficacy and safety of rolapitant for prevention of chemotherapy-
induced nausea and vomiting over multiple cycles of moderately or highly
emetogenic chemotherapy. Eur. J. Cancer 57, 23–30. doi: 10.1016/j.ejca.2015.
12.023
Rapoport, B. L., Chasen, M. R., Gridelli, C., Urban, L., Modiano, M. R.,
Schnadig, I. D., et al. (2015). Safety and efficacy of rolapitant for prevention
of chemotherapy-induced nausea and vomiting after administration of
cisplatin-based highly emetogenic chemotherapy in patients with cancer: two
randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 16,
1079–1089. doi: 10.1016/S1470-2045(15)00035-2
Rapoport, B. L., Jordan, K., Boice, J. A., Taylor, A., Brown, C., Hardwick,
J. S., et al. (2010). Aprepitant for the prevention of chemotherapy-induced
nausea and vomiting associated with a broad range of moderately emetogenic
chemotherapies and tumor types: a randomized, double-blind study. Support
Care Cancer 18, 423–431. doi: 10.1007/s00520-009-0680-9
Schwartzberg, L., Harrow, B., Lal, L. S., Radtchenko, J., and Lyman, G. H. (2015).
Resource utilization for chemotherapy-induced nausea and vomiting events in
patients with solid tumors treated with antiemetic regimens. Am. Health Drug
Benefits 8, 273–282.
Schwartzberg, L. S., Modiano, M. R., Rapoport, B. L., Chasen, M. R., Gridelli, C.,
Urban, L., et al. (2015). Safety and efficacy of rolapitant for prevention
of chemotherapy-induced nausea and vomiting after administration of
moderately emetogenic chemotherapy or anthracycline and cyclophosphamide
regimens in patients with cancer: a randomised, active-controlled, double-
blind, phase 3 trial. Lancet Oncol. 16, 1071–1078. doi: 10.1016/S1470-2045(15)
00034-0
Sun, C. C., Bodurka, D. C., Weaver, C. B., Rasu, R., Wolf, J. K., Bevers, M. W., et al.
(2005). Rankings and symptom assessments of side effects from chemotherapy:
insights from experienced patients with ovarian cancer. Support Care Cancer
13, 219–227. doi: 10.1007/s00520-004-0710-6
Tan, L., Liu, J., Liu, X., Chen, J., Yan, Z., Yang, H., et al. (2009). Clinical
research of Olanzapine for prevention of chemotherapy-induced nausea
and vomiting. J. Exp. Clin. Cancer Res. 28, 131. doi: 10.1186/1756-9966-
28-131
Van Laar, E. S., Desai, J. M., and Jatoi, A. (2015). Professional educational needs
for chemotherapy-induced nausea and vomiting (CINV): multinational survey
Frontiers in Pharmacology | www.frontiersin.org 9 January 2017 | Volume 8 | Article 19
fphar-08-00019 January 27, 2017 Time: 16:55 # 10
Rapoport Delayed CINV: Pathogenesis, Incidence, Management
results from 2388 health care providers. Support Care Cancer 23, 151–157.
doi: 10.1007/s00520-014-2325-x
Varubi (2015). Waltham, MA: Tesaro. Available at: http://varubirx.com/
downloads/VARUBI_(rolapitant)_Full_Prescribing_Information.pdf
[Accessed 25th October, 2016].
Vidall, C., Dielenseger, P., Farrell, C., Lennan, E., Muxagata, P., Fernandez-
Ortega, P., et al. (2011). Evidence-based management of chemotherapy-induced
nausea and vomiting: a position statement from a European cancer nursing
forum. Ecancermedicalscience 5:211. doi: 10.3332/ecancer.2011.211
Weinstein, C., Jordan, K., Green, S. A., Camacho, E., Khanani, S., Beckford-
Brathwaite, E., et al. (2016). Single-dose fosaprepitant for the prevention
of chemotherapy-induced nausea and vomiting associated with moderately
emetogenic chemotherapy: results of a randomized, double-blind phase III trial.
Ann. Oncol. 27, 172–178. doi: 10.1093/annonc/mdv482
Yu, S., Burke, T. A., Chan, A., Kim, H. K., Hsieh, R. K., Hu, X., et al.
(2015). Antiemetic therapy in Asia Pacific countries for patients receiving
moderately and highly emetogenic chemotherapy–a descriptive analysis
of practice patterns, antiemetic quality of care, and use of antiemetic
guidelines. Support Care Cancer 23, 273–282. doi: 10.1007/s00520-014-
2372-3
Conflict of Interest Statement: BLR has received honoraria and expenses from
Herron, Merck and Co. and Tesaro, has sat on advisory boards for Herron, Merck
and Co. and Tesaro and has received research funding from Merck and Co. and
Tesaro.
Copyright © 2017 Rapoport. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 10 January 2017 | Volume 8 | Article 19
